Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

T-Cell Non-Hodgkin Lymphomas: Spectrum of Disease and the Role of Imaging in the Management of Common Subtypes

  • Park, Hye Sun (Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • McIntosh, Lacey (Department of Imaging, Dana Farber Cancer Institute, Harvard Medical School) ;
  • Braschi-Amirfarzan, Marta (Department of Imaging, Dana Farber Cancer Institute, Harvard Medical School) ;
  • Shinagare, Atul B. (Department of Imaging, Dana Farber Cancer Institute, Harvard Medical School) ;
  • Krajewski, Katherine M. (Department of Imaging, Dana Farber Cancer Institute, Harvard Medical School)
  • Received : 2016.07.19
  • Accepted : 2016.08.24
  • Published : 2017.01.01
⟨ Previous Next ⟩

Abstract

T-cell non-Hodgkin lymphomas (NHLs) are biologically diverse, uncommon malignancies characterized by a spectrum of imaging findings according to subtype. The purpose of this review is to describe the common subtypes of T-cell NHL, highlight important differences between cutaneous, various peripheral and precursor subtypes, and summarize imaging features and the role of imaging in the management of this diverse set of diseases.

Keywords

References

  1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-3918
  2. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375-2390 https://doi.org/10.1182/blood-2016-01-643569
  3. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-4130 https://doi.org/10.1200/JCO.2008.16.4558
  4. Abouyabis AN, Shenoy PJ, Lechowicz MJ, Flowers CR. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma 2008;49:2099-2107 https://doi.org/10.1080/10428190802455867
  5. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265-276 https://doi.org/10.1182/blood-2005-06-2508
  6. Vinnicombe SJ, Reznek RH. Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S42-S55 https://doi.org/10.1007/s00259-003-1159-4
  7. Raanani P, Shasha Y, Perry C, Metser U, Naparstek E, Apter S, et al. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol 2006;17:117-122 https://doi.org/10.1093/annonc/mdj024
  8. Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29:1844-1854 https://doi.org/10.1200/JCO.2010.32.5225
  9. Feeney J, Horwitz S, Gonen M, Schoder H. Characterization of T-cell lymphomas by FDG PET/CT. AJR Am J Roentgenol 2010;195:333-340 https://doi.org/10.2214/AJR.09.3665
  10. Tatsumi M, Cohade C, Nakamoto Y, Fishman EK, Wahl RL. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 2005;237:1038-1045 https://doi.org/10.1148/radiol.2373040555
  11. Cronin CG, Swords R, Truong MT, Viswanathan C, Rohren E, Giles FJ, et al. Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol 2010;194:W91-W103 https://doi.org/10.2214/AJR.09.2637
  12. Moskowitz CH, Schoder H. Current status of the role of PET imaging in diffuse large B-cell lymphoma. Semin Hematol 2015;52:138-142 https://doi.org/10.1053/j.seminhematol.2015.01.004
  13. Gill H, Liang RH, Tse E. Extranodal natural-killer/T-cell lymphoma, nasal type. Adv Hematol 2010;2010:627401
  14. Levine BD, Seeger LL, James AW, Motamedi K. Subcutaneous panniculitis-like T-cell lymphoma: MRI features and literature review. Skeletal Radiol 2014;43:1307-1311 https://doi.org/10.1007/s00256-014-1879-5
  15. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007;143:854-859
  16. National Cancer Institute. $PDQ^{(R)}$ adult treatment editorial board. PDQ mycosis fungoides and the Sezary syndrome treatment. Web site. http://www.cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq. Accessed June 28, 2016.
  17. Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 2000;18:2908-2925 https://doi.org/10.1200/JCO.2000.18.15.2908
  18. Kuo PH, McClennan BL, Carlson K, Wilson LD, Edelson RL, Heald PW, et al. FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma. Mol Imaging Biol 2008;10:74-81 https://doi.org/10.1007/s11307-007-0127-y
  19. Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011;29:2598-2607 https://doi.org/10.1200/JCO.2010.32.0630
  20. Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med 2006;47:1326-1334
  21. Ueda T, Hosoki N, Isobe K, Yamamoto S, Motoori K, Shinkai H, et al. Diffuse pulmonary involvement by mycosis fungoides: high-resolution computed tomography and pathologic findings. J Thorac Imaging 2002;17:157-159 https://doi.org/10.1097/00005382-200204000-00009
  22. Baser S, Onn A, Lin E, Morice RC, Duvic M. Pulmonary manifestations in patients with cutaneous T-cell lymphomas. Cancer 2007;109:1550-1555 https://doi.org/10.1002/cncr.22567
  23. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003;139:857-866
  24. Spaccarelli N, Gharavi M, Saboury B, Cheng G, Rook AH, Alavi A. Role of (18)F-fluorodeoxyglucose positron emission tomography imaging in the management of primary cutaneous lymphomas. Hell J Nucl Med 2014;17:78-84
  25. Kim JS, Jeong YJ, Sohn MH, Lim ST, Kim DW, Jeong HJ, et al. Before and after treatment 18F-FDG PET/CT images in a patient with cutaneous T-cell lymphoma. Eur J Nucl Med Mol Imaging 2010;37:1995 https://doi.org/10.1007/s00259-010-1548-4
  26. Damsky WE, Choi J. Genetics of cutaneous T cell Lymphoma: from bench to bedside. Curr Treat Options Oncol 2016;17:33 https://doi.org/10.1007/s11864-016-0410-8
  27. Vergier B, de Muret A, Beylot-Barry M, Vaillant L, Ekouevi D, Chene G, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. Blood 2000;95:2212-2218
  28. Salhany KE, Cousar JB, Greer JP, Casey TT, Fields JP, Collins RD. Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study. Am J Pathol 1988;132:265-277
  29. Herrmann JL, Hughey LC. Recognizing large-cell transformation of mycosis fungoides. J Am Acad Dermatol 2012;67:665-672 https://doi.org/10.1016/j.jaad.2011.12.011
  30. Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 1998;92:1150-1159
  31. Chott A, Dragosics B, Radaszkiewicz T. Peripheral T-cell lymphomas of the intestine. Am J Pathol 1992;141:1361-1371
  32. Bekkenk MW, Vermeer MH, Jansen PM, van Marion AM, Canninga-van Dijk MR, Kluin PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood 2003;102:2213-2219 https://doi.org/10.1182/blood-2002-07-1960
  33. Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011;117:3402-3408 https://doi.org/10.1182/blood-2010-09-310342
  34. Savage KJ, Ferreri AJ, Zinzani PL, Pileri SA. Peripheral T-cell lymphoma--not otherwise specified. Crit Rev Oncol Hematol 2011;79:321-329 https://doi.org/10.1016/j.critrevonc.2010.07.007
  35. Vose JM. Peripheral T-cell non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 2008;22:997-1005, x https://doi.org/10.1016/j.hoc.2008.07.010
  36. Wang T, Feldman AL, Wada DA, Lu Y, Polk A, Briski R, et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood 2014;123:3007-3015 https://doi.org/10.1182/blood-2013-12-544809
  37. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059-3068 https://doi.org/10.1200/JCO.2013.54.8800
  38. Shustov AR, Savage KJ. Does high-dose therapy and autologous hematopoietic stem cell transplantation have a role in the primary treatment of peripheral T-cell lymphomas? ASH evidence-based review 2008. Hematology Am Soc Hematol Educ Program 2008;2008:39-41 https://doi.org/10.1182/asheducation-2008.1.39
  39. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474-2479 https://doi.org/10.1182/blood-2003-09-3080
  40. Dupuis J, Emile JF, Mounier N, Gisselbrecht C, Martin-Garcia N, Petrella T, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood 2006;108:4163-4169 https://doi.org/10.1182/blood-2006-04-017632
  41. Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010;51:25-30 https://doi.org/10.2967/jnumed.109.067892
  42. Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol 2013;31:240-246
  43. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-5504 https://doi.org/10.1182/blood-2008-01-134270
  44. Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 2014;124:1473-1480 https://doi.org/10.1182/blood-2014-04-571091
  45. Lee DY, Lee JJ, Kim JY, Park SH, Chae SY, Kim S, et al. (18)F-FDG PET in patients with primary systemic anaplastic large cell lymphoma: differential features according to expression of anaplastic lymphoma kinase. Nucl Med Mol Imaging 2013;47:249-256 https://doi.org/10.1007/s13139-013-0224-6
  46. Panwalkar AW, Armitage JO. T-cell/NK-cell lymphomas: a review. Cancer Lett 2007;253:1-13 https://doi.org/10.1016/j.canlet.2006.11.018
  47. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009;113:3931-3937 https://doi.org/10.1182/blood-2008-10-185256
  48. Ahn HK, Suh C, Chuang SS, Suzumiya J, Ko YH, Kim SJ, et al. Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis. Ann Oncol 2012;23:2703-2707 https://doi.org/10.1093/annonc/mds096
  49. Ou CH, Chen CC, Ling JC, Chai JW, Wu CH, Chen WH, et al. Nasal NK/T-cell lymphoma: computed tomography and magnetic resonance imaging findings. J Chin Med Assoc 2007;70:207-212 https://doi.org/10.1016/S1726-4901(09)70359-4
  50. Zhou X, Lu K, Geng L, Li X, Jiang Y, Wang X. Utility of PET/CT in the diagnosis and staging of extranodal natural killer/T-cell lymphoma: a systematic review and meta-analysis. Medicine (Baltimore) 2014;93:e258 https://doi.org/10.1097/MD.0000000000000258
  51. Wu HB, Wang QS, Wang MF, Li HS, Zhou WL, Ye XH, et al. Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas. Nucl Med Commun 2010;31:195-200 https://doi.org/10.1097/MNM.0b013e32833310fa
  52. Li YX, Fang H, Liu QF, Lu J, Qi SN, Wang H, et al. Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring. Blood 2008;112:3057-3064 https://doi.org/10.1182/blood-2008-05-160176
  53. Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006;24:181-189 https://doi.org/10.1200/JCO.2005.03.2573
  54. Pan ZH, Huang HQ, Lin XB, Xia YF, Xia ZJ, Peng YL, et al. [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases]. Ai Zheng 2005;24:1493-1497
  55. Kim GE, Lee SW, Chang SK, Park HC, Pyo HR, Kim JH, et al. Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol 2001;61:261-269 https://doi.org/10.1016/S0167-8140(01)00428-5
  56. Li CC, Tien HF, Tang JL, Yao M, Chen YC, Su IJ, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 2004;100:366-375 https://doi.org/10.1002/cncr.11908
  57. Willemze R, Jansen PM, Cerroni L, Berti E, Santucci M, Assaf C, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 2008;111:838-845 https://doi.org/10.1182/blood-2007-04-087288
  58. Jeong SI, Lim HS, Choi YR, Kim JW, Park MH, Cho JS, et al. Subcutaneous panniculitis-like T-cell lymphoma of the breast. Korean J Radiol 2013;14:391-394 https://doi.org/10.3348/kjr.2013.14.3.391
  59. Papajik T, Myslivecek M, Sedova Z, Buriankova E, Prochazka V, Koranda P, et al. Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma. Eur J Haematol 2011;86:32-37 https://doi.org/10.1111/j.1600-0609.2010.01532.x
  60. Lim GY, Hahn ST, Chung NG, Kim HK. Subcutaneous panniculitis-like T-cell lymphoma in a child: whole-body MRI in the initial and follow-up evaluations. Pediatr Radiol 2009;39:57-61
  61. Hoelzer D, Gokbuget N, Digel W, Faak T, Kneba M, Reutzel R, et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002;99:4379-4385 https://doi.org/10.1182/blood-2002-01-0110
  62. Otero HJ, Jagannathan JP, Prevedello LM, Johnston CJ, Ramaiya NH, Van den Abbeele AD, et al. CT and PET/CT findings of T-cell lymphoma. AJR Am J Roentgenol 2009;193:349-358 https://doi.org/10.2214/AJR.08.1398
  63. Morel P, Lepage E, Brice P, Dupriez B, D'Agay MF, Fenaux P, et al. Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J Clin Oncol 1992;10:1078-1085 https://doi.org/10.1200/JCO.1992.10.7.1078
  64. Cortelazzo S, Ponzoni M, Ferreri AJ, Hoelzer D. Lymphoblastic lymphoma. Crit Rev Oncol Hematol 2011;79:330-343 https://doi.org/10.1016/j.critrevonc.2010.12.003
  65. Gokbuget N, Wolf A, Stelljes M, Huttmann A, Buss EC, Viardot A, et al. Favorable outcome in a large cohort of prospectively treated adult patients with T-lmphoblastic lymphoma (T-LBL) despite slowly evolving complete remission assessed by conventional radiography. Blood 2014;124:370
  66. Lepretre S, Touzart A, Vermeulin T, Picquenot JM, Tanguy-Schmidt A, Salles G, et al. Pediatric-like acute lymphoblastic leukemia therapy in adults with lymphoblastic lymphoma: the GRAALL-LYSA LL03 study. J Clin Oncol 2016;34:572-580
  67. Aljurf M, Zaidi SZ. Chemotherapy and hematopoietic stem cell transplantation for adult T-cell lymphoblastic lymphoma: current status and controversies. Biol Blood Marrow Transplant 2005;11:739-754 https://doi.org/10.1016/j.bbmt.2005.07.001
  68. Kaiser U, Uebelacker I, Havemann K. Non-Hodgkin's lymphoma protocols in the treatment of patients with Burkitt's lymphoma and lymphoblastic lymphoma: a report on 58 patients. Leuk Lymphoma 1999;36:101-108 https://doi.org/10.3109/10428199909145953
  69. Coleman CN, Picozzi VJ Jr, Cox RS, McWhirter K, Weiss LM, Cohen JR, et al. Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 1986;4:1628-1637 https://doi.org/10.1200/JCO.1986.4.11.1628
  70. Slater DE, Mertelsmann R, Koziner B, Higgins C, McKenzie S, Schauer P, et al. Lymphoblastic lymphoma in adults. J Clin Oncol 1986;4:57-67 https://doi.org/10.1200/JCO.1986.4.1.57
  71. Song KW, Barnett MJ, Gascoyne RD, Chhanabhai M, Forrest DL, Hogge DE, et al. Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. Ann Oncol 2007;18:535-540
  72. Mohty B, Mohty M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. Blood Cancer J 2011;1:e16 https://doi.org/10.1038/bcj.2011.14
  73. Afessa B, Peters SG. Major complications following hematopoietic stem cell transplantation. Semin Respir Crit Care Med 2006;27:297-309 https://doi.org/10.1055/s-2006-945530

Cited by

  1. The inhibitory effect of MEG3/miR-214/AIFM2 axis on the growth of T-cell lymphoblastic lymphoma vol.51, pp.1, 2017, https://doi.org/10.3892/ijo.2017.4006
  2. T-Cell Lymphoma: Clinical Presentation and Therapeutic Outcome from a Tertiary Care Hospital in Eastern India vol.2, pp.2, 2020, https://doi.org/10.1007/s42399-019-00215-w
  3. Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma vol.12, pp.8, 2017, https://doi.org/10.3390/cancers12082293
  4. Methyl Jasmonate Cytotoxicity and Chemosensitization of T Cell Lymphoma In Vitro Is Facilitated by HK 2, HIF-1α, and Hsp70: Implication of Altered Regulation of Cell Survival, pH Homeostasis, Mi vol.12, pp.None, 2017, https://doi.org/10.3389/fphar.2021.628329
  5. Critical concepts and management recommendations for cutaneous T‐cell lymphoma: A consensus‐based position paper from the Italian Group of Cutaneous Lymphoma vol.39, pp.3, 2017, https://doi.org/10.1002/hon.2832